PMID- 37758851
OWN - NLM
STAT- MEDLINE
DCOM- 20240112
LR  - 20240112
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
VI  - 39
IP  - 2
DP  - 2024 Feb
TI  - Plasma catestatin levels are related to metabolic parameters in patients with 
      essential hypertension and type 2 diabetes mellitus.
PG  - 144-159
LID - 10.1007/s00380-023-02318-w [doi]
AB  - Catestatin (CST) is a pleiotropic peptide with cardioprotective and metabolic 
      effects. CST is involved in the pathogenesis of both arterial hypertension (AH) 
      and type 2 diabetes mellitus (T2DM), which are the risk factors of cardiovascular 
      diseases. In this study, we aimed to investigate the plasma CST levels in 
      hypertensive patients, especially with T2DM, as well as compare those with 
      healthy volunteers, and explore the relationship between CST levels and clinical, 
      anthropometric and laboratory parameters. 106 Hypertensive patients, 55 of which 
      had comorbidity T2DM, and 30 healthy volunteers were enrolled in the study. All 
      subjects underwent clinical examination, including vital signs and anthropometric 
      data assessment, medical history interview, and blood sample collection. Plasma 
      CST levels were measured by an enzyme-linked immunosorbent assay (ELISA), using a 
      commercial diagnostic kit. The plasma CST levels were significantly lower in 
      hypertensive patients (N = 106) compared with healthy subjects (N = 30) 
      (5.02 +/- 1.09 vs. 6.64 +/- 0.72; p < 0.001). Furthermore, hypertensive patients with 
      T2DM (N = 55) have significantly reduced CST levels in comparison with those 
      without T2DM (N = 51) (4.47 +/- 1.16 vs. 5.61 +/- 0.61; p < 0.001). CST significantly 
      correlated with anthropometric characteristics, in particular, weight 
      (r =  - 0.344; p < 0.001), BMI (r =  - 0.42; p < 0.001), neck (r =  - 0.358; 
      p < 0.001), waist (r =  - 0.487; p < 0.001), hip (r =  - 0.312; p < 0.001), wrist 
      circumferences (r =  - 0.264; p = 0.002), and waist-to-hip ratio (r =  - 0.395; 
      p < 0.001). Due to its antihypertensive effect, CST has significant associations 
      with systolic BP (r =  - 0.475; p < 0.001) and duration of AH (r =  - 0.26; 
      p = 0.007). CST also has an inverse relationship with insulin (r =  - 0.382; 
      p < 0.001), glucose (r =  - 0.45; p < 0.001), index HOMA-IR (r =  - 0.481; 
      p < 0.001) and HbA1c (r =  - 0.525; p < 0.001), that indicate its involvement in 
      T2DM development. Besides, CST has significant correlations with uric acid levels 
      (r =  - 0.412; p < 0.001) as well as lipid parameters, especially HDL-C 
      (r = 0.480; p < 0.001), VLDL-C (r =  - 0.238; p = 0.005), TG (r =  - 0.4; 
      p < 0.001), non-HDL-C/HDL-C (r =  - 0.499; p < 0.001). Multiple linear regression 
      analysis indicated BMI (beta =  - 0.22; p = 0.007), AH duration (beta =  - 0.25; 
      p = 0.008), HbA1c (beta =  - 0.43; p = 0.019) and HDL-C levels (beta = 0.27; p = 0.001) 
      as independent predictors of CST levels. The hypertensive patients have 
      significantly decreased CST levels that are even more reduced in the presence of 
      comorbid T2DM. The established correlations with anthropometric and laboratory 
      parameters indicate not only antihypertensive but also metabolic effects of CST. 
      Our results suggest the probable role of CST in the pathophysiology of 
      cardiometabolic diseases and the development of cardiovascular complications.
CI  - (c) 2023. Springer Nature Japan KK, part of Springer Nature.
FAU - Pankova, Olena
AU  - Pankova O
AUID- ORCID: 0000-0002-8027-2406
AD  - Department of General Practice-Family Medicine, Kharkiv National Medical 
      University, Heroiv Kharkova Ave., 275, Kharkiv, 61106, Ukraine. 
      dr.helen.pankova@gmail.com.
FAU - Korzh, Oleksii
AU  - Korzh O
AUID- ORCID: 0000-0001-6838-4360
AD  - Department of General Practice-Family Medicine, Kharkiv National Medical 
      University, Heroiv Kharkova Ave., 275, Kharkiv, 61106, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20230927
PL  - Japan
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
RN  - 0 (chromogranin A (344-364))
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Peptide Fragments)
RN  - 0 (Chromogranin A)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/epidemiology
MH  - Glycated Hemoglobin
MH  - Antihypertensive Agents
MH  - Body Mass Index
MH  - Essential Hypertension
MH  - *Hypertension/complications/epidemiology
MH  - *Insulin Resistance
MH  - Blood Glucose/analysis
MH  - *Peptide Fragments
MH  - *Chromogranin A
OTO - NOTNLM
OT  - Arterial hypertension
OT  - Catestatin
OT  - Insulin resistance
OT  - Obesity
OT  - Type 2 diabetes mellitus
EDAT- 2023/09/28 00:42
MHDA- 2024/01/12 06:43
CRDT- 2023/09/27 23:29
PHST- 2023/05/18 00:00 [received]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2024/01/12 06:43 [medline]
PHST- 2023/09/28 00:42 [pubmed]
PHST- 2023/09/27 23:29 [entrez]
AID - 10.1007/s00380-023-02318-w [pii]
AID - 10.1007/s00380-023-02318-w [doi]
PST - ppublish
SO  - Heart Vessels. 2024 Feb;39(2):144-159. doi: 10.1007/s00380-023-02318-w. Epub 2023 
      Sep 27.